China, India
Ko Diagnostic Imaging Inoponesa Sei Hupenyu muMazhinji Hondo dzeMyeloma?
Unoda kuziva kuti nzira yekurapa iri kuponesa sei hupenyu hwevarwere vakawanda vemyeloma? Verenga blog yedu kuti udzidze zvakawanda nezve iyi nzira yekuponesa hupenyu! Ngativhure peji regomarara pamwe chete. Nyaya yako yetariro inotangira pano. Hell..
anti-BCMA, BCMA CAR-T, chimeric antigen receptor T cell therapy, China, Immune thrombocytopenia, E.T.C
Anti-BCMA CAR T-Cell kurapa kwekiriniki miedzo yekudzokazve/refractory Immune thrombocytopenia(R/R ITP)
Kurume 2023: Immune thrombocytopenia (ITP) chirwere chinogona kutungamira kune nyore kana kuwandisa maronda uye kubuda ropa. Vanosvika zvikamu zviviri kubva muzvitatu zvevarwere vanowana kuregererwa mushure / panguva yekurapa kwekutanga. Nekudaro, chimwe chikamu che..
hwokushandura zvinhu zvipenyu, MOTO - T Cell kurapwa, MOTO T-Cell, CAR kurapwa, China, fund raise, Oricell Therapeutics
Oricell inokwidza imwe $45M USD kuwedzera CAR T-Cell therapy kuUnited States
Kurume 23, 2023: Makiriniki uye ekutanga-danho rekurapa cancer maseru ari kugadzirwa neShanghai biotech Oricell awana imwe madhora makumi mana neshanu emari, kambani yakazivisa neChipiri. Kutevera kuratidzwa kuAS..
Beijing, MUKATI-4, CARVYKTI, China, ciltacabtagene autoleucel, Clinical trials, Legend biotech, inokanganisa akawanda myeloma, Shanghai
Legend Biotech Inozivisa Chikamu 3 CARTITUDE-4 Chidzidzo cheCARVYKTI®(ciltacabtagene autoleucel) Yakawana Mhedzisiro Yayo Yekutanga muKurapwa kweVarwere Vakadzokerazve uye Refractory Multiple Myeloma.
JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), kambani yepasi rose yebiotechnology inogadzira, kugadzira uye kushambadzira nzira dzekurapa dzekurapa zvirwere zvinouraya, yakazivisa nhasi kuti ..
Beijing, hwokushandura zvinhu zvipenyu, Cell kurapwa, Serura kurapwa, China, Cilta-Cel, ciltacabtagene autoleucel, Legend biotech
Legend Biotech Inosheedzera Kugamuchirwa Kwekushandisa Kwayo Kutsva Mushonga weCiltacabtagene Autoleucel (Cilta-Cel) muChina.
SOMERSET, NJ— JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), kambani yepasi rose yebiotechnology iri kuvandudza, kugadzira nekutengesa mishonga mitsva yekurapa zvirwere zvinouraya, gore.
China, Clinical trials, hepatocellular carcinoma, JW Therapeutics, Shanghai
JW Therapeutics Inozivisa Kutanga kweClinical Study yeJWATM214 muVarwere vane Advanced Hepatocellular Carcinoma.
SHANGHAI, CHINA, Kukadzi 28, 2023 - JW Therapeutics (HKEX: 2126), yakazvimiririra uye inovandudza biotechnology kambani inotarisana nekugadzira, kugadzira uye kutengesa zvigadzirwa zvema cell immunotherapy, yakazivisa iyo init.
American Society yeHematology, Carteyva, China, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Inopa Yazvino Clinical Dhata paCarteyva® muFollicular Lymphoma uye Mantle Cell Lymphoma paMusangano Wepagore wechi64 ASH.
SHANGHAI, CHINA, Zvita 12, 2022 Kambani yakazvimirira uye yekugadzira biotechnology inonzi JW Therapeutics (HKEX: 2126) inotarisa mukugadzira, kugadzira, uye kutengesa zvigadzirwa zvema cell immunotherapy. Pa64th American Society ..
Cell kurapwa, China, JW Therapeutics, Shanghai
JW Therapeutics Inozivisa Kuti Cell Yayo Immunotherapy Mishonga Yakabudirira Kubatsira Varwere mazana matatu.
SHANGHAI, CHINA, Mbudzi 9, 2022 - JW Therapeutics (HKEX: 2126), yakazvimiririra uye inovandudza biotechnology kambani inotarisa mukugadzira, kugadzira, uye kushambadzira cell immunotherapy zvigadzirwa, yakazivisa kuti kubva kuN.
2makumi manomwe ehupenyu, China, immunotherapy, JW Therapeutics, ushamwari
JW Therapeutics uye 2seventy bio Inozivisa Strategic Kudyidzana Kuti Ikurumidze Tsvagiridzo uye Kukudziridzwa kweT-cell-based Immunotherapies.
SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherap..
China, Enhertu, HER 2 positive
Enhertu yakatenderwa kuChina kune varwere vane HER2-positive metastatic cancer yemazamu
Kukadzi 2023: Enhertu (trastuzumab deruxtecan) kubva kuAstraZeneca uye Daiichi Sankyo yakabvumidzwa senge monotherapy yekurapa varwere vakuru vane isingarambike kana metastatic HER2-positive cancer yemazamu vakagamuchira ..